Tissue Factor in Infection and Severe Inflammation

Marcel Levi; Tom van der Poll; Hugo ten Cate

doi:10.1055/s-2006-933338

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2006; 32(1): 033-039
DOI: 10.1055/s-2006-933338

Tissue Factor in Infection and Severe Inflammation

Marcel Levi¹ , Tom van der Poll¹ ^, ² , Hugo ten Cate³

¹Department of Internal Medicine, Academic Hospital Maastricht, Maastricht, The Netherlands
²Laboratory of Experimental Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
³Department of Internal Medicine, Academic Hospital Maastricht, Maastricht, The Netherlands

Abstract

ABSTRACT

In the pathogenesis of vascular disease, inflammation and coagulation play a pivotal role. Increasing evidence points to an extensive cross-talk between these two systems, whereby inflammation not only leads to activation of coagulation, but coagulation also considerably affects inflammatory activity. Tissue factor (TF) plays an important role at the crossroad of coagulation and inflammation, as the principal initiator of coagulation and an important modulator of inflammation. Proinflammatory cytokines can induce TF expression on mononuclear cells and endothelial cells and thereby commence pathways that lead to thrombin generation. Simultaneously, TF may bind to cellular receptors, which may affect the production and release of inflammatory mediators. There is increasing experimental evidence that TF inhibition may have beneficial effects in disease states in which the combination of coagulation and inflammation plays a prominent role.

KEYWORDS

Coagulation - inflammation - infection - tissue factor - mononuclear cells - endothelium

Full Text

References

REFERENCES

1 Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341 586-592
2 Wheeler A P, Bernard G R. Treating patients with severe sepsis. N Engl J Med. 1999; 340 207-214
3 Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004; 124 567-576
4 Levi M, van der Poll T, Büller H R. Bidirectional relation between inflammation and coagulation. Circulation. 2004; 109 2698-2704
5 Esmon C T. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?. Blood. 2000; 95 1113-1116
6 Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002; 8 1257-1262
7 Levi M, van der Poll T, ten Cate H, van Deventer S J. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997; 27 3-9
8 Levi M, Keller T T, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res. 2003; 60 26-39
9 Esmon C T. The regulation of natural anticoagulant pathways. Science. 1987; 235 1348-1352
10 Biemond B J, Levi M, ten Cate H et al.. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci. 1995; 88 587-594
11 Levi M, ten Cate H, Bauer K A et al.. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994; 93 114-120
12 Pixley R A, De La Cadena R A, Page J D et al.. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest. 1993; 91 61-68
13 Kalter E S, Daha M R, ten Cate J W, Verhoef J, Bouma B N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis. 1985; 151 1019-1027
14 Ruf W, Edgington T S. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J. 1994; 8 385-390
15 Mann K G, van't Veer C, Cawthern K, Butenas S. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis. 1998; 9(suppl 1) S3-S7
16 Camerer E, Kolsto A B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 1996; 81 1-41
17 Banner D W, D'Arcy A, Chene C et al.. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996; 380 41-46
18 ten Cate H, Bauer K A, Levi M et al.. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993; 92 1207-1212
19 Bauer K A, Kass B L, ten Cate H, Hawiger J J, Rosenberg R D. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990; 76 731-736
20 Østerud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis. 1998; 9(suppl 1) S9-14
21 Neumann F J, Marx N, Gawaz M et al.. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997; 95 2387-2394
22 Edgington T S, Mackman N, Fan S T, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouvelle Revue Français d'Hematologie. 1992; 34(suppl) S15-S27
23 Giesen P L, Rauch U, Bohrmann B et al.. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 1999; 96 2311-2315
24 Østerud B, Rao L V, Olsen J O. Induction of tissue factor expression in whole blood-lack of evidence for the presence of tissue factor expression on granulocytes. Thromb Haemost. 2000; 83 861-867
25 Nieuwland R, Berckmans R J, McGregor S et al.. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000; 95 930-935
26 Koyama T, Nishida K, Ohdama S et al.. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol. 1994; 87 343-347
27 Taylor F BJ, Chang A, Ruf W et al.. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991; 33 127-134
28 Biemond B J, Levi M, ten Cate H et al.. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost. 1995; 73 223-230
29 Zimmerman G A, McIntyre T M, Prescott S M, Stafforini D M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002; 30 S294-S301
30 Shebuski R J, Kilgore K S. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002; 300 729-735
31 Broze Jr G J. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 1995; 46 103-112
32 Novotny W F, Brown S G, Miletich J P, Rader D J, Broze Jr G J. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991; 78 387-393
33 Ameri A, Kuppuswamy M N, Basu S, Bajaj S P. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 1992; 79 3219-3226
34 Gando S, Kameue T, Morimoto Y et al.. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002; 30 1729-1734
35 Levi M. The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit Care Med. 2002; 30 1914-1915
36 Sandset P M, Warn-Cramer B J, Rao L V, Maki S L, Rapaport S I. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA. 1991; 88 708-712
37 Randolph M M, White G L, Kosanke S D et al.. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli-a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli . Thromb Haemost. 1998; 79 1048-1053
38 Park C T, Creasey A A, Wright S D. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood. 1997; 89 4268-4274
39 de Jonge E, Dekkers P E, Creasey A A et al.. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000; 95 1124-1129
40 Roque M, Reis E D, Fuster V et al.. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol. 2000; 36 2303-2310
41 Creasey A A, Chang A C, Feigen L et al.. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993; 91 2850-2856
42 Erlich J H, Boyle E M, Labriola J et al.. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol. 2000; 157 1849-1862
43 Abraham E, Reinhart K, Svoboda P et al.. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001; 29 2081-2089
44 Zoldhelyi P, Chen Z Q, Shelat H S, McNatt J M, Willerson J T. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci USA. 2001; 98 4078-4083
45 Abraham E, Reinhart K, Opal S et al.. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290 238-247
46 De Pont A C, Moons A H, de Jonge E et al.. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J Thromb Haemost. 2004; 2 65-70
47 Coughlin S R. Thrombin signalling and protease-activated receptors. Nature. 2000; 407 258-264
48 Cunningham M A, Romas P, Hutchinson P, Holdsworth S R, Tipping P G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood. 1999; 94 3413-3420
49 Versteeg H H, Peppelenbosch M P, Spek C A. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?. Thromb Haemost. 2001; 86 1353-1359
50 de Jonge E, Friederich P W, Levi M, van der Poll T. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin-6 and interleukin-8 release in healthy human subjects. Clin Diagn Lab Immunol. 2003; 10 495-497
51 Sambrano G R, Weiss E J, Zheng Y W, Huang W, Coughlin S R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001; 413 74-78
52 Sabri A, Guo J, Elouardighi H et al.. Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem. 2003; 278 11714-11720
53 Marutsuka K, Hatakeyama K, Sato Y et al.. Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res. 2002; 107 271-276
54 Aird W C. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med. 2001; 29 S28-S34
55 Aird W C, Edelberg J M, Weiler-Guettler H et al.. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol. 1997; 138 1117-1124
56 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999; 340 1555-1564
57 Miller D L, Welty-Wolf K, Carraway M S et al.. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol. 2002; 26 650-658
58 Welty-Wolf K E, Carraway M S, Miller D L et al.. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med. 2001; 164 1988-1996
59 Moons A H, Levi M, Peters R J. Tissue factor and coronary artery disease. Cardiovasc Res. 2002; 53 313-325

Marcel LeviM.D. Ph.D.

Department of Vascular Medicine and Internal Medicine (F-4), Academic Medical Center, University of Amsterdam

Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Email: m.m.levi@amc.uva.nl